Novus Therapeutics Inc (NASDAQ:NVUS) President Catherine C. Turkel acquired 33,680 shares of the stock in a transaction dated Wednesday, September 12th. The stock was acquired at an average price of $4.78 per share, with a total value of $160,990.40. Following the completion of the acquisition, the president now owns 61,567 shares in the company, valued at approximately $294,290.26. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of NVUS opened at $5.10 on Friday. Novus Therapeutics Inc has a fifty-two week low of $3.12 and a fifty-two week high of $8.61.
Novus Therapeutics (NASDAQ:NVUS) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.03). sell-side analysts forecast that Novus Therapeutics Inc will post -1.22 EPS for the current fiscal year.
An institutional investor recently raised its position in Novus Therapeutics stock. Derby & Company Inc. lifted its holdings in Novus Therapeutics Inc (NASDAQ:NVUS) by 60.3% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 29,545 shares of the biopharmaceutical company’s stock after acquiring an additional 11,111 shares during the quarter. Derby & Company Inc. owned 0.31% of Novus Therapeutics worth $149,000 at the end of the most recent quarter. Institutional investors and hedge funds own 41.19% of the company’s stock.
Novus Therapeutics Company Profile
Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).
Featured Story: Market Capitalization – What it Means for Investors
Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.